NCT07528391Not yet recruiting
Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus
Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus: A Cluster Randomised Controlled Trial in Rural China
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
The COMPACT-HTDM study is a parallel, two-arm cluster randomized controlled trial designed to evaluate a comorbidity-oriented integrated primary care management model for elderly patients with coexisting hypertension and type 2 diabetes mellitus in community health centers and township health centers. The trial aims to determine whether an integrated comorbidity management package can improve metabolic control and cardiovascular risk management compared with usual disease-specific care in routine primary care settings. Clusters are primary care facilities randomized 1:1 to intervention or control by an independent statistician using a computer-generated random sequence. Patients aged 60-74 years with diagnosed hypertension and type 2 diabetes for at least six months and recent use of chronic disease management services at the study site will be recruited through chronic disease registries. The intervention includes comorbidity-focused medication optimization and safety management, integrated lifestyle management, self-management and community support, training for primary care staff, standardized toolkits and workflow embedding, an integrated comorbidity management platform, and feedback/incentive mechanisms. The control group will continue current standard primary care management for hypertension and diabetes under existing national guidelines. Participants will be followed for six months, with possible extension to 12 months for longer-term outcomes. The primary outcome is the proportion of participants achieving both blood pressure and glycemic control targets, defined as SBP/DBP \<130/80 mmHg and HbA1c \<7.0%. Secondary outcomes include BMI, blood lipids, medication adherence, lifestyle behaviors, follow-up completion, referral rate, and safety events such as hypoglycemia and hypotension; implementation outcomes include acceptability, fidelity, and feasibility.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 960 (estimated)
- First submitted
- 1 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Nanchang University
- Diseases
- High blood pressure, Type 2 diabetes
- NCT number
- NCT07528391
What you commit to
- Study type: Interventional
- Planned participants: 960
- From 1 May 2026 to the primary completion date, 30 Apr 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Facilities currently participating in other intervention studies or pilot programs targeting hypertension and/or diabetes management that may interfere with the study intervention.
- Severe cognitive impairment or psychiatric illness affecting participation or follow-up.
Other
- Cluster Level (Primary Care Facilities):
- Facilities with major organizational instability (e.g., restructuring, closure, or significant staff turnover) that would affect implementation or follow-up.
- Individual Level:
- Anticipated inability to complete 6-month follow-up.
Who the study is looking for
- Cluster level (primary care facilities):
- Township health centers or community health service centers that provide routine primary care management services for both hypertension and diabetes.
- Agree to participate in cluster randomization and study procedures.
- Have basic capacity for chronic disease follow-up and data recording.
- Individual participant level (patients):
- Aged 60 to 74 years.
- Diagnosed with hypertension and type 2 diabetes mellitus for at least 6 months.
- Received at least one chronic disease management service at the participating study site within the past 6 months.
- Able to provide written informed consent.
Age in the registry: 60 years to 74 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.